- Patent Title: JAK kinase inhibitor compounds for treatment of respiratory disease
-
Application No.: US16689706Application Date: 2019-11-20
-
Publication No.: US10913740B2Publication Date: 2021-02-09
- Inventor: Paul R. Fatheree , John R. Jacobsen , Gary E. L. Brandt , Noah Benjamin , Marta Dabros , Venkat R. Thalladi
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
- Current Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agent Jeffrey A. Hagenah; Florence Jovic
- Main IPC: A61K31/437
- IPC: A61K31/437 ; A61K31/416 ; A61P43/00 ; A61P11/06 ; A61P11/00 ; C07D471/04

Abstract:
The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
Public/Granted literature
- US20200087303A1 JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease Public/Granted day:2020-03-19
Information query
IPC分类: